NEW YORK — Paige has signed a distribution agreement to integrate its flagship digital pathology software platform with Mindpeak's BreastIHC AI-based tool for breast cancer analysis, the companies said on Tuesday.
BreastIHC is designed to detect, classify, and quantify breast cancer cells, helping to differentiate between tumorous and non-tumorous structures on a single-cell basis. Under the terms of the deal, it will be offered within the Paige Platform to enable real-time results for routine breast cancer immunohistochemistry biomarkers, the companies said.
Financial and other terms were not disclosed.
BreastIHC is CE-IVD marked and available for research-use-only outside of the EU, and Hamburg, Germany-based Mindpeak is aiming for US Food and Drug Administration clearance in 2023.
In late 2020, New York City-based Paige partnered with Agendia to codevelop breast cancer treatment planning tools.